Skip to Main Content

After winning regulatory approval late last month for its new multiple sclerosis drug, Biogen (BIIB) boasted to a patient group that its pill would cost $88,000, which meant it would have the “lowest annual” wholesale price of any such medicine.

The move was apparently designed to appease critics who have complained that prices for multiple sclerosis treatments are not only too high, but have been continually rising over time, which has been noted in several studies over the past few years.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.